Develops immunotherapies using its proprietary T-cell receptor (TCR) technology. Focuses on treatments for cancer, infectious diseases, and autoimmune conditions. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 82% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 82% a year on average.
Sales run at $297.6M a year. A small number, but proof the product has real buyers.
A loss of $26.4M against $297.6M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 21/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 46/100.
On our five-subject report card, IMCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMCR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (46/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.